ArticleThe journal of pathology. Clinical research2026
Tumor-type-specific expression of TTF-1 in primary central nervous system tumors classified by the 2021 WHO criteria.
Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid transcription factor-1 (TTF-1) is a widely used immunohistochemical marker for tumors of thyroid and pulmonary origin; however, its expression profile and diagnostic relevance in primary central nervous system (CNS) tumors remain incompletely characterized, particularly following the revisions in the 2021 WHO Classification of CNS Tumors. We systematically evaluated TTF-1 expression in a cohort of 214 primary CNS tumors diagnosed between 2021 and 2024 at The First Affiliated Hospital of China Medical University and classified according to current WHO criteria. Immunohistochemistry for TTF-1 was performed, and expression patterns were correlated with histological tumor type, molecular classification, and WHO grade. Statistical analyses were conducted to compare expression frequencies across tumor subtypes. TTF-1 showed tumor-specific expression patterns. It was highly sensitive in central neurocytomas (89.47%) and fully specific for subependymal giant cell astrocytoma (SEGA) among circumscribed gliomas. Focal TTF-1 positivity was sporadically detected in high-grade diffuse gliomas, without significant links to molecular alterations, anatomical sites, or other common immunohistochemical indicators. TTF-1 was consistently negative in multiple newly classified and rare CNS tumors, whereas partial intracranial mesenchymal tumors with FET-CREB fusions presented TTF-1 positivity. In conclusion, TTF-1 serves as a reliable sensitive marker for central neurocytomas and a highly specific marker for SEGA. Given its occasional positivity in high-grade gliomas and certain intracranial mesenchymal tumors, pathologists should interpret TTF-1 results prudently to avoid misdiagnosing primary CNS lesions as metastatic tumors. TTF-1 is therefore a valuable auxiliary biomarker for difficult differential diagnosis of CNS tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.